ArticleJournal of cellular and molecular medicine2026
Longchai Decoction Treated the Fibrosis of Liver Induced by CCl
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacological Potential of Selenoproteins in the Regulation of Oxidative Stress in Liver Diseases.Pharmaceutics · 2026Review
- Dual Roles of Natural Products in Regulating Ferroptosis in Acute and Chronic Liver Diseases: A Review.Oxidative medicine and cellular longevity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study is to evaluate the therapeutic efficacy of Longchai Decoction (LCD), an empirical traditional Chinese medicine formula for liver disorders, on liver fibrosis (LF) and to elucidate its molecular mechanisms. A mouse model of LF and an erastin-induced ferroptosis model was established in LX-2 cells, which were then treated with silybin and LCD. The therapeutic function of LCD on liver fibrosis was evaluated using biochemical assays, histopathological staining, transmission electron microscopy, transcriptome sequencing, and immunohistochemistry. The mechanisms by which LCD alleviated LF were investigated using western blotting and immunofluorescence. LCD treatment significantly decreased the serum concentrations of IL-1β, IL-6, and TNF-α. It also effectively suppressed lipid peroxidation, diminished iron accumulation, and preserved mitochondrial integrity within hepatic tissues. Transcriptome sequencing analysis revealed that LCD significantly increased the levels of genes including NRF2, GPX4, and HO-1, thereby modulating the Nrf2/GPX4 pathway both in vivo and in vitro, thereby inhibiting lipid peroxidation and ferroptosis. Our findings suggest that LCD plays a protective role against hepatocyte ferroptosis and mitigates CCl4-induced liver damage and fibrosis through the activation of the Nrf2/GPX4 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.